TABLE 1.
Patient sample cohorts utilized in this study
| Source and cohort no. | Infectiona | No. of patients | No. of samples |
|---|---|---|---|
| Confounding infection pilot studyb | |||
| 1 | Aspergillus | 20 | 20 |
| 2 | Chlamydia | 20 | 20 |
| 3 | Mycoplasma | 19 | 19 |
| 4 | Normal | 31 | 31 |
| VF training set | 18 | 18 | |
| Valley fever patient sera with non-VF controlsc | |||
| 1 | VF training set (U of A) | 35 | 55 |
| 2 | VF test set (U of A) | 25 | 67 |
| 3 | Normal individuals (ASU) | 41 | 41 |
| 4 | Influenza vaccinees (2006-2007 seasonal vaccine) (ASU) | 7 | 7 |
a
U of A, University of Arizona; ASU, Arizona State University.
b
The samples for the confounding infection pilot study were obtained from SeraCare Life Sciences (Milford, MA).
c
The samples from the VF training set were obtained from John Galgiani, MD, Valley Fever Center for Excellence (Tucson, AZ).